Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson
Medtronic

Last Updated: August 13, 2022

Details for Patent: 7,915,275


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,915,275 protect, and when does it expire?

Patent 7,915,275 protects XIFAXAN and is included in one NDA.

This patent has ninety-four patent family members in thirty-seven countries.

Summary for Patent: 7,915,275
Title:Use of polymorphic forms of rifaximin for medical preparations
Abstract: The present invention relates to Rifaximin polymorphic forms .alpha., .beta. and .gamma., to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.
Inventor(s): Viscomi; Giuseppe C. (Bologna, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Bologna, IT), Barbanti; Miriam (Bologna, IT), Calanni; Fiorella (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:11/873,841
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,915,275
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Formulation;

Drugs Protected by US Patent 7,915,275

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. See Plans and Pricing
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,915,275

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI03A2144Nov 7, 2003

International Family Members for US Patent 7,915,275

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 043547 See Plans and Pricing
Argentina 081991 See Plans and Pricing
Argentina 081992 See Plans and Pricing
Austria 361927 See Plans and Pricing
Austria 421965 See Plans and Pricing
Austria 421966 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
Merck
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.